Pre-clinical PET data in non-human primates has demonstrated the efficacy of drug candidate TM38837 in treating obesity, type 2 diabetes and related metabolic disorders.
The drug, developed by biotech company 7TM Pharma, is designed to avoid the risk of psychiatric side effects through its restriction to peripherally located CB1 receptors in the body.
The study showed the drug to have a greater propensity to cross the blood-brain barrier than other brain-penetrant CB1 receptor antagonists, without causing depression or anxiety.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData